Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: A pilot study

Carol L. Karp; Anat Galor; Yunhee Lee; Sonia H. Yoo

doi:10.3109/09273948.2010.486687

Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: A pilot study

Carol L. Karp, Anat Galor, Yunhee Lee, Sonia H. Yoo

Ophthalmology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.

Original language	English (US)
Pages (from-to)	254-260
Number of pages	7
Journal	Ocular Immunology and Inflammation
Volume	18
Issue number	4
DOIs	https://doi.org/10.3109/09273948.2010.486687
State	Published - Aug 2010

Keywords

Conjunctival intraepithelial neoplasia
Ocular surface squamous neoplasia
Pegylated interferon

ASJC Scopus subject areas

Ophthalmology
Immunology and Allergy

Access to Document

10.3109/09273948.2010.486687

Fingerprint Dive into the research topics of 'Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: A pilot study'. Together they form a unique fingerprint.

Cite this

@article{27b57bc707f5447cafb043d1772e7bf5,

title = "Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: A pilot study",

abstract = "Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.",

keywords = "Conjunctival intraepithelial neoplasia, Ocular surface squamous neoplasia, Pegylated interferon",

author = "Karp, {Carol L.} and Anat Galor and Yunhee Lee and Yoo, {Sonia H.}",

note = "Funding Information: This research was supported in part by an unrestricted grant from Research to Prevent Blindness (RPB), New York, NY. Funding Information: Received 19 May 2009; revised 06 August 2009; accepted 10 August 2009 This study was supported by an unrestricted grant from Research to Support the Blind. Correspondence: Carol L. Karp, MD, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136, USA. E-mail: ckarp@med. miami.edu Copyright: Copyright 2010 Elsevier B.V., All rights reserved.",

year = "2010",

month = aug,

doi = "10.3109/09273948.2010.486687",

language = "English (US)",

volume = "18",

pages = "254--260",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia

T2 - A pilot study

AU - Karp, Carol L.

AU - Galor, Anat

AU - Lee, Yunhee

AU - Yoo, Sonia H.

N1 - Funding Information: This research was supported in part by an unrestricted grant from Research to Prevent Blindness (RPB), New York, NY. Funding Information: Received 19 May 2009; revised 06 August 2009; accepted 10 August 2009 This study was supported by an unrestricted grant from Research to Support the Blind. Correspondence: Carol L. Karp, MD, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136, USA. E-mail: ckarp@med. miami.edu Copyright: Copyright 2010 Elsevier B.V., All rights reserved.

PY - 2010/8

Y1 - 2010/8

N2 - Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.

AB - Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.

KW - Conjunctival intraepithelial neoplasia

KW - Ocular surface squamous neoplasia

KW - Pegylated interferon

UR - http://www.scopus.com/inward/record.url?scp=77954869515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954869515&partnerID=8YFLogxK

U2 - 10.3109/09273948.2010.486687

DO - 10.3109/09273948.2010.486687

M3 - Article

C2 - 20662655

AN - SCOPUS:77954869515

VL - 18

SP - 254

EP - 260

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 4

ER -

Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: A pilot study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this